文献速递胸部MRCT

定量相位分辨功能肺MRI预测结缔组织病相关间质性肺疾病进展

Quantitative Phase-resolved Functional Lung MRI Prediction of Disease Progression in Connective Tissue Disease-associated Interstitial Lung Disease.
PubMed 文献 · Radiology · 2026-01-01

前瞻性研究纳入172名参与者(143名女性,平均年龄59岁),在基线和1年随访中评估相位分辨功能肺(PREFUL)MRI的通气与灌注参数对结缔组织病相关间质性肺疾病(CTD-ILD)进展的预测价值;多参数PREFUL模型预测进展的AUC为0.87(95%CI:0.78,0.95),高于其他逻辑回归模型(P=0.004,P<0.001)。

要点

  • 进展组CTD-ILD基线灌注缺损(26.5%±9.1)高于稳定组(14.7%±6.8),通气血流匹配健康区(62.1%±10.8)低于稳定组(75.6%±8.9)。
  • 多参数PREFUL模型预测CTD-ILD进展的AUC为0.87(95%CI:0.78,0.95),优于其他逻辑回归模型。
  • CTD-ILD患者动态通气(0.95 au±0.05)低于健康对照(0.97 au±0.02),灌注(22.0 mL/min每100 mL±9.2)低于对照(50.3 mL/min每100 mL±16.2)。

核心结论

  • 在CTD-ILD参与者中,PREFUL MRI衍生的通气与灌注参数刻画了不同的肺部灌注表型,并与1年内的疾病进展相关。

研究设计与样本

  • 前瞻性研究,2024年5月至2025年4月,纳入172名参与者(平均年龄59岁±11.8[SD],143名女性),包括无肺疾病健康对照和CTD-ILD患者,均接受基线PREFUL MRI、胸部CT和肺功能检查,CTD-ILD患者随访1年。

关键影像表现/征象

  • 与健康对照相比,CTD-ILD患者动态通气降低(均值0.97 au±0.02 vs 0.95 au±0.05,P < .001)。
  • 与健康对照相比,CTD-ILD患者灌注降低(均值50.3 mL/min每100 mL±16.2 vs 22.0 mL/min每100 mL±9.2,P < .001)。

诊断标准与关键数值

  • 疾病进展定义为满足以下标准中至少两项:用力肺活量绝对值下降超过预计值5%,或肺一氧化碳弥散量绝对值下降超过预计值10%,或CT证据显示疾病进展,或呼吸道症状加重。
  • 多参数PREFUL模型预测疾病进展的AUC为0.87(95%CI:0.78,0.95),与其他逻辑回归模型比较P=0.004、P<0.001。
  • 基线时进展组CTD-ILD较稳定组灌注缺损更高(均值14.7%±6.8 vs 26.5%±9.1,P < .001)。
  • 基线时进展组CTD-ILD较稳定组健康通气血流匹配更低(均值75.6%±8.9 vs 62.1%±10.8,P = .001)。

临床应用与阅片要点

  • PREFUL MRI可定量评估CTD-ILD患者的通气与灌注异常,多参数模型有助于预测1年内疾病进展。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Background Connective tissue disease-associated interstitial lung disease (CTD-ILD) is a spatially and temporally heterogeneous disease. Determining whether CTD-ILD is in a progressive stage is crucial for guiding clinical management. Purpose To determine whether CTD-ILD is associated with ventilation and perfusion parameters quantified with phase-resolved functional lung (PREFUL) MRI and whether these functional parameters can help predict CTD-ILD progression. Materials and Methods In this prospective study performed from May 2024 to April 2025, healthy participants without pulmonary disease and participants with CTD-ILD underwent baseline PREFUL MRI, chest CT, and pulmonary function tests. Participants with CTD-ILD were followed up for 1 year. Disease progression was defined as meeting at least two of the following criteria: an absolute decline in forced vital capacity of more than 5% predicted or an absolute decline in diffusing capacity of lung for carbon monoxide of more than 10% predicted, CT evidence of disease progression, or worsening respiratory symptoms. Least absolute shrinkage and selection operator regression were applied to identify variables associated with disease progression, and predictive performance was assessed using the area under the receiver operating characteristic curve (AUC). Results A total of 172 participants (mean age, 59 years ± 11.8 [SD]; 143 women) were included. Compared with controls, participants with CTD-ILD demonstrated reduced dynamic ventilation (mean, 0.97 arbitrary units [au] ± 0.02 vs 0.95 au ± 0.05, respectively; P < .001) and lower perfusion (mean, 50.3 mL/min per 100 mL ± 16.2 vs 22.0 mL/min per 100 mL ± 9.2; P < .001). At baseline, compared with stable CTD-ILD, progressive CTD-ILD was associated with a higher perfusion defect (mean, 14.7% ± 6.8 vs 26.5% ± 9.1; P < .001) and lower healthy ventilation and perfusion matches (mean, 75.6% ± 8.9 vs 62.1% ± 10.8; P = .001). The multiparametric PREFUL model achieved the highest predictive performance (AUC, 0.87; 95% CI: 0.78, 0.95) compared with other logistic models (P = .004, P < .001). Conclusion In participants with CTD-ILD, ventilation and perfusion parameters derived from PREFUL MRI characterized distinct pulmonary perfusion phenotypes in CTD-ILD and were associated with disease progression over 1 year. © RSNA, 2026 Supplemental material is available for this article. See also the editorial by Rahsepar and Abtin in this issue.

来源:Radiology,查看原文。版权归原作者所有。

引用

  1. Ouyang T, Liu Q, Zhang H, et al. Quantitative Phase-resolved Functional Lung MRI Prediction of Disease Progression in Connective Tissue Disease-associated Interstitial Lung Disease. Radiology. 2026. PMID: 42048592. doi:10.1148/radiol.253337

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。